BioNTech's stock dropped about 10% after they ended a Phase 2 trial for an mRNA colorectal cancer vaccine. An independent committee looked at the data and concluded the treatment likely wouldn't be effective. They followed this up with some positive Phase 3 lung cancer trial data for Gotistobart. Median survival was 18.5 months versus 10 months for standard chemo. The market reaction was muted though, mostly because it was an early non-pivotal stage with only 87 patients. The main stage 2 portion is still ongoing. Their Covid vaccine business is still slowing down, but they have other mRNA cancer treatments in the pipeline, like BNT113 for head and neck cancer which currently has FDA fast track status.